Research programme: type 2 diabetes mellitus therapeutics - Albireo ABAlternative Names: IBAT inhibitor (for T2DM) - Albireo
Latest Information Update: 01 Mar 2017
At a glance
- Originator Albireo AB
- Mechanism of Action Sodium-bile acid cotransporter-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Mar 2017 Discontinued - Preclinical for Type-2 diabetes mellitus in Sweden (unspecified route) before March 2017
- 18 Dec 2014 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)